Dr. Cindy S. Bauer, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
1919 E Thomas Rd
Phoenix, AZ 85016
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
AZ license 47355 -
Internal Medicine Physician
AZ license 47355 · WI license 83004
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 12 companies reported 23 payments worth $711 in total to this clinician.
| Genzyme Corporation | $150 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $131 |
| Csl Behring | $93.75 |
| AstraZeneca Pharmaceuticals LP | $61.59 |
| Ars Pharmaceuticals Operations, Inc. | $55.30 |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.47 |
| Biocryst US Sales Co., LLC | $43.84 |
| GlaxoSmithKline, LLC. | $39.11 |
| Food and Beverage | $711 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $262,627 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Sanofi US Services Inc. · Enrolling by invitation · NCT06191315 - A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.